Long Daniel D. sold $533K of SEPN
Long Daniel D. (SVP, Drug Discovery) sold 15,000 shares of Septerna, Inc. (SEPN) at an average of $35.51 ($35.10–$35.97, $0.53M total) across 2 trades on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the officer’s open-market sale amount, price range, and post-sale holdings; it can slightly influence sentiment but does not change the company’s operating outlook.
Market read
Useful for monitoring insider activity, but likely not a standalone catalyst for SEPN’s stock.
What to watch
Traders may over-weight insider sales; without accompanying changes in fundamentals or additional filings, the signal is usually weak.
Background
This is an SEC Form 4 insider transaction disclosure for Septerna, Inc. (SEPN).
Ticker impact
Septerna (SEPN) disclosed an officer (SVP, Drug Discovery) open-market sale of 15,000 shares under a 10b5-1 plan on 2026-06-22.
Low likelihood of a sustained price move solely from this Form 4; any impact is likely short-lived.
The filing is a disclosed open-market sale by an officer with a pre-arranged 10b5-1 plan; it provides a concrete datapoint but not a fundamental change (no guidance, trial, deal, or regulatory action).
Market effects
Minimal; this is company-specific insider transaction with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.
Key entities
- issuerSepterna, Inc.
Subject of the Form 4 insider transaction disclosure (SEPN).
- insiderLong Daniel D.
SVP, Drug Discovery; sold 15,000 shares via open-market sale under a 10b5-1 plan.